Alkermes responds to FDA questions on Vivitrol application

By Elaine Rigoli

Tampa, Fla., Feb. 17 - Alkermes, Inc. announced Friday the submission of a complete response to the approvable letter issued in December 2005 by the Food and Drug Administration regarding the New Drug Application for Vivitrol (naltrexone for extended-release injectable suspension).

Alkermes expects the FDA to classify the complete response as a class 1 resubmission, under which the FDA will seek to complete its review within 60 days from the time of resubmission.

Vivitrol is under review for the treatment of alcohol dependence in combination with a treatment program that includes psychosocial support.

In March 2005, Alkermes submitted an NDA for Vivitrol. In June 2005, Alkermes and Cephalon, Inc. entered into a collaboration agreement to develop and sell Vivitrol in the United States for the treatment of alcohol dependence.

Cambridge, Mass.-based Alkermes is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.